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Abstract Psoriasis is a chronic inflammatory skin disor-
der, which is associated with a significant negative impact
on a patient’s quality of life. Traditional therapies for pso-
riasis are often not able to meet desired treatment goals, and
high-dose and/or long-term use is associated with toxicities
that can result in end-organ damage. An improved under-
standing of the involvement of cytokines in the etiology of
psoriasis has led to the development of biologic agents
targeting tumor necrosis factor (TNF)-a and interleukins
(ILs)-12/23. While biologic agents have improved treat-
ment outcomes, they are not effective in all individuals with
psoriasis. The combination of biologic agents with tradi-
tional therapies may provide improved therapeutic options
for patients who inadequately respond to a single drug or
when efficacy may be increased with supplementation of
another treatment. In addition, combination therapy may
reduce safety concerns and cumulative toxicity, as lower
doses of individual agents may be efficacious when used
together. This article reviews the current evidence available
on the efficacy and safety of combining biologic agents with
systemic therapies (methotrexate, cyclosporine, or reti-
noids) or with phototherapy, and the combination of bio-
logic agents themselves. Guidance is provided to help
physicians identify situations and the characteristics of
patients who would benefit from combination therapy with
a biologic agent. Finally, the potential clinical impact of
biologic therapies in development (e.g., those targeting IL-
17A, IL-17RA, or IL-23 alone) is analyzed.
Key Points
Accumulating evidence supports the administration
of biologic therapies in combination with systemic
agents or phototherapy.
Limited data exist on the co-administration of two
biologics.
Emerging, highly selective biologics may
demonstrate the required efficacy to be administered
as monotherapy.
1 Introduction
Psoriasis is a chronic inflammatory skin disease, which
affects approximately 3 % of the general population in the
USA [1]. The most common form of the disease, plaque
psoriasis, is characterized by the development of chronic
erythematous plaques covered with silvery white scales,
which most commonly appear on the elbows, knees, scalp,
umbilicus, and lumbar regions [2]. Psoriasis has been asso-
ciated with a significant negative impact on the patient’s
quality of life, due to the disfiguring effect of the skin lesions
and, for some, the functional impairment resulting from joint
pain [3]. Additionally, individuals with psoriasis are more
susceptible to specific debilitating comorbidities, including
cardiometabolic dysfunction, fatigue, and depression [4–6].
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The treatment strategy for psoriasis depends on a variety
of factors (e.g., the medical history, tolerability of therapies
and potential for side effects, and disease severity).
Regarding disease severity, there is no commonly accepted
definition of mild versus moderate-to-severe psoriasis [7].
Moreover, a patient may have mild disease on the basis of
body surface area (BSA) involvement, but localization of
lesions in vulnerable areas (e.g., the face, feet, hands, and/
or genitals) may warrant systemic therapy. Some guide-
lines provide specific criteria to help evaluate the severity
of a patient’s psoriasis, but all recognize the importance of
assessing both the physical and psychosocial burden when
considering the best treatment approach [7–10].
The US National Psoriasis Foundation recommends that
patients with BSA involvement \5 % should be consid-
ered candidates for topical therapy, whereas those with
BSA C5 % should be considered candidates for systemic
therapy alone or in combination with phototherapy [9]. A
‘‘rule of tens’’ has also been proposed, whereby
BSA [10 %, Psoriasis Area Severity Index (PASI) [10, or
Dermatology Life-Quality Index (DLQI) [10 identify
patients with severe disease [10]. More recently, a Euro-
pean consensus meeting defined mild psoriasis as
BSA B10 %, PASI B10, and DLQI B10; and moderate-
to-severe psoriasis warranting systemic therapy as BSA or
PASI [10 and DLQI [10 [7]. The American Academy of
Dermatology (AAD) guidelines present a treatment deci-
sion tree based on the presence or absence of psoriatic
arthritis and categorization of psoriasis as ‘‘limited’’ or
‘‘extensive’’ disease, but specific definitions of these terms
are not provided [8].
The ultimate goal of systemic therapy is to eliminate the
systemic inflammatory burden of psoriasis and to com-
pletely clear the skin [7]. Historically, conventional sys-
temic treatment options for psoriasis have included
methotrexate, cyclosporine, and oral retinoids such as ac-
itretin [11]. However, the use of these systemic agents has
been limited by insufficient clinical efficacy, safety con-
cerns, or both [7, 12, 13]. Cyclosporine is generally con-
sidered the most effective of these agents, providing a rapid
response [14]. However, nephrotoxicity, hypertension, and
numerous drug interactions may limit its use. Moreover,
the duration of cyclosporine use is limited when it is pre-
scribed for psoriasis (1 year in the USA, 2 years in the
UK). The hepatotoxic effects of methotrexate necessitate
particular caution when it is used in patients with liver
problems or in those consuming large amounts of alcohol.
Both methotrexate and retinoids are teratogenic [14].
None of these agents fully meets the needs of patients,
and many are contraindicated because of the presence of
comorbidities. Patient dissatisfaction with conventional
systemic therapies has been well documented. Patients
have voiced displeasure over inconvenient administration
of traditional psoriasis therapies and their related side
effects (e.g., hirsutism with cyclosporine, gastrointestinal
intolerance with methotrexate, and hair loss and cheilitis
with acitretin) [13]. Approximately 40 % of patients on
systemic therapy alone have expressed dissatisfaction with
their treatment outcomes [15], and overall patient satis-
faction has been found to be lower with systemic therapy
(cyclosporine, methotrexate, or acitretin) than with bio-
logic agents, biologic/methotrexate combinations, or pho-
totherapy [16]. Dissatisfaction with therapy is a major
contributor to diminished adherence among patients with
dermatologic disorders; inadequate treatment can therefore
add to the already substantial burden of poor health-related
quality of life associated with psoriasis [17, 18].
Over the past two decades, our understanding of the
etiology of psoriasis has evolved; it is now recognized that
both the innate and adaptive immune pathways are
involved in its pathogenesis [19, 20]. Consequently, drugs
that target specific components of the immune responses
involved in the pathogenesis of psoriasis have been
developed in an attempt to improve treatment efficacy,
safety, and tolerability [21]. These agents include biologics
that target cytokines such as tumor necrosis factor (TNF)-a
and interleukins (ILs) 12/23 [21]. Despite remarkable
improvements in psoriasis treatment outcomes with bio-
logic therapy, however, many patients still do not achieve
the desired outcome (Table 1) [22–30], have a prolonged
time to response, or fail to maintain efficacy improvements
over time. Tolerability may also be an issue (e.g., infec-
tions with TNF-a antagonists).
Combination systemic therapy may optimize treatment
outcomes because of the potential of additive or synergistic
efficacy. In addition, the dose of individual agents may be
reduced, thereby decreasing toxicity and improving toler-
ability and compliance [31]. Up to 30 % of patients
receiving a TNF-a antagonist also receive concomitant
treatment with a traditional systemic agent such as meth-
otrexate [32, 33]. Data are more limited with other drug
combinations, including combinations with biologic agents
[21, 31, 34]. In this paper, we review the rationale for the
use of combination therapy in the management of psoriasis,
along with evidence identified through a nonsystematic
review of the literature that is currently available to support
this practice. We also discuss new developments in the
treatment of psoriasis, which may lessen the need for
combination therapy to achieve desired outcomes.
2 Rationale for Combination Therapy
Some of the rationales for combining conventional thera-
pies with biologic agents for psoriasis treatment have a
historical basis in the treatment of psoriatic arthritis. In
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particular, methotrexate has been widely used in combi-
nation with biologic agents in clinical trials involving
patients with psoriatic arthritis [35–39]. Indeed, the AAD
guidelines recommend disease-modifying antirheumatic
drugs (e.g., methotrexate), TNF-a antagonists, or a com-
bination of these agents for moderate to severely active
psoriatic arthritis [40]. The Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
recommends that ‘‘a combination of two or more agents
could be used in those patients who fail to respond to a
single agent, or who present (with) joint damage progres-
sion in spite of treatment’’ [41]. The European League
Against Rheumatism (EULAR) has made similar recom-
mendations, but notes that there is a lack of robust evidence
in psoriatic arthritis for this type of therapy [42].
The basis for these recommendations is rooted in the
potential benefits that combination therapy may offer these
patients, and can be extended to patients with psoriasis.
These rationales include the potential efficacy synergies
that may permit a more complete response and achieve a
response more quickly, or both, as well as a potentially
diminished risk of specific safety concerns that are caused
by broad immunosuppressive therapy or that have been
otherwise associated with conventional therapies (e.g.,
hepatotoxicity, nephrotoxicity, and bone marrow toxicity)
[21, 43]. In addition, because the increased cytokine levels
associated with psoriasis may also be associated with other
inflammatory comorbid conditions, interventions targeting
these upregulated cytokines may also provide a broader
benefit to the patient. For example, a recent literature
review found that methotrexate and TNF-a inhibitors may
reduce cardiovascular events in individuals with psoriasis,
although additional studies are required in this area [44].
Additionally, data from clinical trials evaluating ada-
limumab in rheumatoid arthritis demonstrate that patients
on methotrexate had significantly higher blood levels of
adalimumab than patients treated with adalimumab alone
[30]. Thus, methotrexate, through an unknown mechanism,
may boost drug levels of adalimumab. It is important to
note that exposure to multiple drugs could also increase the
risk of certain side effects, depending on the safety profiles
of the individual agents being combined.
Combination therapies that include biologic agents may
be particularly appropriate for a number of specific groups
of patients with psoriasis (Table 2) [45–48]. The AAD
guidelines do not provide specific recommendations in this
regard [49]. The recent European consensus guidelines
recommend that combination therapy should be considered
for individuals who are switching to a biologic agent and in
whom it may be useful to taper the previous systemic
therapy before discontinuation to prevent a disease flare
[32, 45, 50]. Additionally, patients with complications or
comorbidities may benefit from the use of combination
therapy with biologics. Patients with specific safety or
toxicity concerns, such as methotrexate-related hepatotox-
icity or cyclosporine-related nephrotoxicity, may also
benefit from combination therapy with a biologic agent
[47]. Additionally, combination therapy may help in the
prevention or treatment of adverse events in certain
patients (e.g., use of retinoids in a patient at risk of non-
melanoma skin cancer, or anti-TNF therapy in a patient
with comorbid Crohn’s disease) [45, 51, 52]. Patients who
may benefit from less rigorous treatment regimens with
lower doses may also be candidates for combination ther-
apy [53, 54]. In addition, there may be certain situations in
which it would be appropriate to initiate combination
therapy, such as at times when flares consistently occur
(e.g., in the winter) or when a patient changes insurance
Table 1 Results from clinical trials on the efficacy of biologic








Psoriasis Study I (672 patients)
PASI 75 at week 12 14 % 32 % 47 %
Psoriasis Study II (611 patients)
PASI 75 at week 12 – 32 % 46 %
Ustekinumab (at weeks 0 and 4)
45 mg 90 mg
PHOENIX I (766 patients)
PASI 75 at week 12 67 % 66 %
PHOENIX II (1,230 patients)
PASI 75 at week 12 67 % 76 %
Infliximab (at weeks 0, 2, and 6)
3 mg/kg 5 mg/kg
EXPRESS (378 patients)
PASI 75 at week 10 – 80 %
EXPRESS II (835 patients)
PASI 75 at week 10 70 % 75 %
SPIRIT (249 patients)
PASI 75 at week 10 72 % 88 %
Adalimumab
40 mg EOW
Psoriasis Study I (1,212 patients)
PASI 75 at week 16 71 %
Psoriasis Study II (147 patients)
PASI 75 at week 16 78 %
BIW biweekly, EOW every other week, PASI 75 improvement in the
Psoriasis Area Severity Index of C75 %, QW once weekly
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and there are concerns about possible disruptions in
therapy.
3 Clinical Experience with Combination Therapy
Although combination therapy with biologic agents has
been widely used in the treatment of rheumatoid arthritis
and psoriatic arthritis, only a few small-scale, randomized,
controlled trials have been undertaken in patients with
psoriasis [21, 31, 34, 48, 55]. In many cases, studies of
combination therapy with biologic agents have been con-
ducted against a background of treatment with conven-
tional systemic therapies, such as methotrexate, in
individuals without an adequate response to such treatment.
Additionally, many of these studies were performed in
patients with psoriatic arthritis; the effect of therapy on
their psoriasis was also recorded as a secondary consider-
ation [35–39]. Recently, the European consensus meeting
developed recommendations for combining biologic and
conventional systemic psoriasis therapies to provide some
degree of structure for this practice; these recommenda-
tions are reported in Table 3 [50].
3.1 Combinations Involving Methotrexate
Initial findings of improved skin clearance in individuals
with psoriatic arthritis after treatment with methotrexate
and adalimumab led to further investigation of combined
methotrexate and biologic therapy in psoriasis-specific
populations [36]. In an open-label pilot study of 59 patients
with active psoriasis (PASI C8, BSA [10 %, or both)
without an adequate response to long-term (C3 months)
methotrexate therapy, patients were randomized to receive
either etanercept and continued methotrexate or etanercept
with methotrexate tapered and discontinued [56]. After
24 weeks, the proportion of patients with a Physicians’
Global Assessment (PGA) rating of ‘‘clear’’ or ‘‘almost
clear’’ was significantly higher in the combination therapy
group than in the etanercept monotherapy group (66.7
versus 37.0 %, respectively; P = 0.025). The same trend
was also observed in the improvement of PASI scores by at
least 75 % (PASI 75) at weeks 12 and 24. The adverse
event rates were 75.0 % in the monotherapy group and
61.3 % in the combination group; adverse infectious events
were the most frequent (25.0 and 38.7 %, respectively)
[56]. The recent comparison of efficacy between etanercept
and etanercept in combination with methotrexate by
Gottlieb et al. [57] is one of the most robust combination
trials to date in patients with moderate-to-severe psoriasis.
Almost 45 % of patients in this trial had received prior
systemic therapy, including methotrexate in about 17 % of
patients. In this randomized, double-blind trial of 478
patients (BSA C10 %, PASI C10), PASI 75 response rates
at 24 weeks were significantly higher with combination
therapy than with etanercept alone (77.3 versus 60.3 %,
respectively; P \ 0.0001), as were other PASI response
rates (Fig. 1) [57]. Combination therapy was also associ-
ated with a significant increase in the proportion of patients
with a PGA rating of ‘‘clear’’ or ‘‘almost clear’’, compared
with etanercept alone (week 12: 65.5 versus 47.0 %; week
24: 71.8 versus 54.3 %; both P = 0.01). Adverse events
were reported in 74.9 % of patients receiving combination
therapy and in 59.8 % of those receiving etanercept
monotherapy; the adverse event profiles of the two treat-
ments were similar and included nasopharyngitis (9.6 %
with combination therapy versus 10.9 % with mono-
therapy), headache (9.2 versus 9.2 %), and upper respira-
tory tract infection (8.4 versus 5.0 %).
The combination of methotrexate and biologic agents
also improves psoriasis in individuals without previous
methotrexate therapy. The multicenter, randomized, open-
label RESPOND trial (N = 115) evaluated the efficacy of
methotrexate alone or in combination with infliximab in
patients with psoriasis and psoriatic arthritis who had not
previously received methotrexate [58]. The mean weekly
dose of methotrexate was 15.4 mg in the monotherapy
group and 14.6 mg in the combination group; the combi-
nation group received infliximab 5 mg/kg at weeks 0, 2, 6,
and 14. The baseline PASI scores were relatively low
compared with those in most psoriasis trials, with mean
scores of approximately 11.6 in the monotherapy group and
8.3 in the combination group. Among patients with base-
line PASI measurements of C2.5, the PASI 75 response
rate at 16 weeks (a secondary outcomes measure) was
97.1 % with combination therapy and 54.3 % with meth-
otrexate alone (P \ 0.0001). Treatment-related adverse
events occurred in 46 % of patients in the combination




• Inadequate efficacy of monotherapies
• Tolerability concerns
• Complications or comorbidities (e.g., psoriatic arthritis, cardiovascular disease)
• Bridging treatment in patients switching between systemic therapies
• Potential for intermittent or continuous use during long-term treatment for relapsing disease
• Tailoring therapy to meet individual patients’ needs
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Table 3 Recommendations for combining biologic therapies with conventional systemic therapy in patients with moderate-to-severe plaque
psoriasis
Efficacy and safety of combination therapy
1. There is no approved indication for any combination of a biologic agent with conventional systemic therapies in psoriasis
2. A conventional systemic therapy can be added to biologic monotherapy with the intention to improve efficacy, optimize the risk–benefit
profile, reduce the risk of immunogenicity (with methotrexate), and enhance long-term disease management
3. For TNF antagonists, combination with methotrexate (5–15 mg/week) is safe and increases the long-term efficacy of the treatment regimen
4. Because of the lack of evidence and the potentially increased toxicity (e.g., an increased skin cancer risk), the combination of TNF
antagonists or ustekinumab with cyclosporine should be used with caution
5. The combination of etanercept 25 mg/week with acitretin showed efficacy similar to that of 2 9 25 mg/week etanercept monotherapy. The
combination of acitretin with lower doses of etanercept 25 mg/week has a safety profile comparable to that of monotherapy
6. The combination of adalimumab with acitretin may be considered
7. A treatment combination of methotrexate with ustekinumab may be used, but there are limited data on safety and efficacy
8. Data on the combination of acitretin with infliximab or ustekinumab are not currently available, but an increased clinical response might
also be expected
Optimal safety monitoring of combination therapy
1. The optimal safety monitoring for combination therapy has not been determined
2. All parameters recommended to be monitored for each drug as monotherapy should be assessed
3. As a practical guide, the monitoring interval should be defined by the drug with the most stringent monitoring criteria
4. If synergistic toxicity is suspected, monitoring intervals may need to be reduced and additional parameters may need to be added
Patients with no response or insufficient response to combination therapy
1. The combination of a biologic with a conventional systemic therapy is an option in the treatment of psoriasis; however, there is no clinical
trial evidence on which to provide answers to these questions
2. Conventional systemic therapy with methotrexate or acitretin can be added to a biologic monotherapy with the intention to improve
efficacy, optimize the risk–benefit profile, reduce the risk of immunogenicity (with methotrexate), and enhance long-term disease
management. The conventional systemic therapy should be added beginning with the lowest recommended dosage (e.g., 5–10 mg/week for
methotrexate). The combined use of cyclosporine and a biologic raises safety concerns
3. If an adequate response is still not achieved:
– Optimize the current therapy (e.g., increase the dosage of the conventional systemic therapy; increase the dose or decrease the treatment
interval of the biologic)
– Consider switching to another biologic drug
Adapted from Mrowietz et al. [50], with permission.  2013 The Authors. Journal of the European Academy of Dermatology and Venereology
 2013 European Academy of Dermatology and Venereology
TNF tumor necrosis factor
Fig. 1 Proportions of patients
with moderate-to-severe plaque
psoriasis showing
improvements in the Psoriasis
Area Severity Index of C50 %
(PASI 50), C75 % (PASI 75),
and C90 % (PASI 90) at 12 and
24 weeks during treatment with
etanercept, alone or combined
with methotrexate. Reproduced
with permission from Gottlieb
et al. [57].  2012 The Authors.
BJD  2012 British Association
of Dermatologists
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group and in 24 % of patients receiving methotrexate
alone. The most common treatment-related adverse events
were increased levels of hepatic enzymes.
Randomized trials investigating the combination of
adalimumab and methotrexate are lacking in psoriasis,
although positive results have been reported among
patients with rheumatoid arthritis [59, 60]. The findings of
the aforementioned randomized trials are further supported
by numerous uncontrolled studies and case series that have
shown beneficial effects of combinations of biologic ther-
apies with methotrexate in patients with psoriasis or pso-
riatic arthritis [45, 61–76]. These studies have provided
useful insights into the effectiveness and tolerability of
combination therapy in routine clinical practice.
Wee et al. [72] retrospectively investigated the safety of
infliximab infusions in 59 patients with psoriasis who
received infliximab over a 9-year period at a single center
in the UK. In this study, 56 % of patients were receiving
concomitant systemic therapies; 41 % were receiving
methotrexate [72]. Overall, acute infusion reactions were
associated with 10 of 858 infliximab infusions (1.2 %), of
which three (0.3 %) were severe. The incidence of infusion
reactions was significantly lower in patients receiving inf-
liximab with methotrexate than in those receiving inflix-
imab alone (4 versus 27 %, respectively; P = 0.05),
potentially as a result of decreased formation of anti-inf-
liximab antibodies due to methotrexate. Another recent
study (n = 45) investigated the effectiveness of combina-
tion therapy with methotrexate and adalimumab (11 treat-
ment episodes) or adalimumab dose escalation (i.e., weekly
dosing; 32 treatment episodes) in patients with psoriasis (a
subset of approximately 25 % also had psoriatic arthritis)
[74]. Patients were included in this study if they had an
inadequate response, determined by the physician’s dis-
cretion, to standard adalimumab dosing. Combination
therapy resulted in PASI 50 response rates of 9 % after
12 weeks and 18 % after 24 weeks; the corresponding
values in patients with increased adalimumab doses were
25 and 35 %, respectively. The mean weekly dose of
methotrexate used in this study was 9.5 mg per treatment
episode. Adverse event rates were not reported in this trial;
no serious adverse events were judged by the investigators
to be related to the study medication. The study was too
small to draw definitive conclusions but suggests that, at
least for some patients, adalimumab dose escalation may
be more beneficial than adding methotrexate.
3.2 Combinations Involving Cyclosporine
Cyclosporine therapy allows for regulation of the immune
system through a different mechanism of action than cur-
rent biologic agents, and their combination may improve
control of lesion formation. The efficacy of therapy with
cyclosporine and adalimumab was investigated in a non-
randomized, open-label study in patients with active pso-
riatic arthritis that was refractory to methotrexate treatment
[77]. After 12 months, PASI 50 response criteria were met
by 95 % of patients receiving combination therapy, com-
pared with 85 % of patients receiving adalimumab alone
and 65 % of those receiving cyclosporine alone
(P = 0.003 versus combination treatment). In a small-
scale, open-label study of patients with refractory psoriasis
(n = 7), combination therapy with etanercept and low-dose
cyclosporine (200 mg/day initially, then 100 mg/day)
resulted in a mean reduction in PASI scores of 93.2 % at
the end of the maintenance treatment period [78]. In
addition, combinations of cyclosporine with biologic
therapies have also been studied in a number of nonran-
domized trials and case reports [45, 65–67, 79–82]. More
rigorous studies are required to validate the safety and
efficacy of these treatment regimens. Care must be taken
when prescribing cyclosporine, because of concerns about
nephrotoxicity, hypertension, and numerous drug interac-
tions. Patients receiving cyclosporine in combination with
other agents that suppress the immune system, such as
TNF-a inhibitors, should be closely monitored for devel-
opment of infections. Additionally, cyclosporine is not an
option for long-term treatment of psoriasis, because of
cumulative toxicity concerns.
3.3 Combinations Involving Retinoids
Individuals with psoriasis, many of whom have had sig-
nificant phototherapy or excessive sun exposure, are at an
increased risk of nonmelanoma skin cancers, such as
squamous cell carcinoma and basal cell carcinoma [83]. To
help reduce the risk of these types of cancer, oral retinoids
may be given in combination with other systemic therapies.
This method of treatment decreases the incidence of actinic
keratosis and squamous cell carcinoma [31, 45, 84] but
may also improve the underlying psoriasis. In a random-
ized, controlled, investigator-blinded pilot study, 60
patients with moderate-to-severe chronic plaque psoriasis
were randomized to receive acitretin (0.4 mg/kg daily),
etanercept (25 mg twice weekly), or the two agents in
combination with reduced etanercept dosing (25 mg eta-
nercept once weekly plus acitretin 0.4 mg/kg daily) [53].
At 24 weeks, a PASI 75 response was achieved in 30 % of
patients receiving acitretin alone, compared with 45 % of
those receiving etanercept alone and 44 % of those
receiving combination therapy (P = 0.001 for both eta-
nercept groups versus acitretin; Fig. 2) [53]. All treatments
were well tolerated, and the only reported adverse event
was mild mucosal dryness in two patients in the acitretin
group and one patient in the combined group. No malig-
nancies were reported.
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Efficacious treatment of psoriasis using combinations of
biologic therapies with retinoids has also been reported in a
number of uncontrolled studies and case reports [45, 64,
66, 67, 85–90].
3.4 Phototherapy–Drug Combinations
Although phototherapy is not a pharmacologic interven-
tion, it is an important treatment modality in the manage-
ment of psoriasis. The combination of etanercept and
narrow-band ultraviolet B (NB-UVB) or etanercept alone
were studied in a trial of 75 patients with moderate-to-
severe psoriasis that had not reached PASI 90 after
12 weeks of etanercept monotherapy [91]. The investiga-
tors observed that there were significant challenges to NB-
UVB therapy adherence, with only 21.6 % of patients
receiving C80 % of NB-UVB treatments. After 24 weeks,
there was no significant difference in PASI 75 response
rates between patients receiving etanercept monotherapy
and those receiving the combination of etanercept and NB-
UVB. However, in a small subset of patients with high
adherence to NB-UVB therapy, PASI 75 response rates
were found to be significantly improved as compared with
patients receiving etanercept alone. Poor adherence to
NB-UVB therapy was also observed by Park et al. [92] in
an etanercept combination trial of obese patients with
psoriasis. Interestingly, the combination of etanercept and
NB-UVB did not lead to greater clearance of psoriasis than
etanercept alone in these patients, and the investigators
speculated that the poor adherence to NB-UVB therapy
may have been due to patient satisfaction with the degree
of psoriasis improvement from etanercept monotherapy. As
with the other combination modalities, a number of
uncontrolled clinical trials have shown positive results
when NB-UVB therapy was combined with etanercept,
adalimumab, and ustekinumab [93–99]. Thus, combina-
tions of biologics and phototherapy may increase efficacy
but are limited by adherence to therapy and concerns
regarding the potential for skin cancer formation.
3.5 Combinations Involving Biologics
The combination of biologic agents has not been studied
thoroughly in clinical trials, because of the relatively
recent adoption of their use and concerns over blocking
two pathways of the immune system. Thus, there are
limited data available on the efficacy and safety of this
type of therapy. A single case report has described suc-
cessful treatment of psoriasis with adalimumab and us-
tekinumab in a patient who had not responded to
combination therapy with methotrexate and ustekinumab
[45]. However, the combination of biologic therapies did
not improve this patient’s psoriatic arthritis. Physicians
should proceed cautiously when considering the use of
combinations of biologic agents; experience with this
approach is very limited at this time and may have
unknown consequences.
4 Clinical Implications and Unanswered Questions
Although the studies reviewed above have provided some
evidence that therapies combining a conventional agent
with a biologic are more effective than those agents used
alone, and may be well tolerated in patients with psoriasis,
there are still a number of questions that remain regarding
the most appropriate use of this strategy [31]. Some of the
trials involved patients with psoriatic arthritis and included
those with psoriasis disease severity below the criteria for
psoriasis trials, or had small sample sizes, or measured
efficacy using inadequate or low efficacy endpoints (e.g.,
PASI 50). It is necessary to identify the safest and most
effective combinations to limit potentially dangerous
adverse events while achieving higher rates of skin clear-
ance. In addition, the long-term safety of combination
therapy is of particular concern; data are not available from
controlled trials. Combination therapy with biologics may
be beneficial in the management of comorbidities com-
monly found in patients with psoriasis. For instance, both
TNF-a inhibitors and methotrexate reduce the risk of
Fig. 2 Psoriasis Area Severity Index of C50 % (PASI 50)
and C75 % (PASI 75) response rates at 24 weeks in patients with
active plaque psoriasis treated with acitretin, etanercept twice weekly,
or the two agents in combination with reduced use of etanercept
(etanercept once weekly plus daily acitretin) [53]
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cardiovascular events, but it is unknown if their combina-
tion would produce additional benefits [44]. To fully
understand the potential positive or negative influence of
combination therapy on comorbidities, additional studies
are required. Patients with psoriasis are also more likely to
develop other health issues such as metabolic syndrome,
which may be affected by combination therapy. TNF-a
inhibitors may improve insulin resistance and fasting glu-
cose levels, suggesting a possible beneficial role in man-
aging metabolic syndrome, but other studies have reported
increases in total cholesterol and high-density lipoprotein
cholesterol following treatment [44]. Likewise, further
studies are needed to elucidate the effect of combination
therapy on metabolic syndrome. Combination therapy may
be a more cost-effective method of managing psoriasis, but
economic evaluations are needed to determine potential
savings in healthcare costs. Disease management for
patients with severe psoriasis could be improved, particu-
larly if the findings to date with short-term use of photo-
therapy or traditional systemic agents in combination with
biologic therapy are confirmed in the long term. Finally, it
remains to be determined if biologic therapies can be used
in combination without an increased safety risk.
5 Emerging Biologics
A number of new biologic therapies are currently in
development for the treatment of psoriasis (Table 4) [100–
103], including those that target IL-17A or its receptor, IL-
23, and T cells [21]. It is not yet known how these thera-
pies, many of which are in phase III clinical trials, will fit
into the psoriasis treatment paradigm. These agents offer
the potential for selective targeting of key processes in the
pathogenesis of psoriasis. For example, compared with
TNF-a, IL-17A is a cytokine that is downstream in the
psoriasis pathogenesis pathway. As such, inhibiting this
cytokine or its receptor may theoretically block psoriatic
plaque formation without disrupting upstream cytokines
that may be involved in other processes. Downstream
blockade therefore has the potential to lessen the unwanted
off-target effects associated with more upstream blockade.
This selective targeting may also translate into a high level
of efficacy, potentially reducing the need for combination
therapy and offering patients a more convenient method to
meet their treatment goals.
6 Conclusions
There is evidence demonstrating that combination therapy
with biologic agents and conventional systemic therapies
or phototherapy is effective and well tolerated in the
management of moderate-to-severe psoriasis, although
there are several limitations with respect to existing data
(e.g., many psoriatic arthritis trials; patients often had less
severe psoriasis; small studies; assessment of PASI 50 and
not PASI 75 as the primary efficacy measure). Combina-
tion therapy offers the potential for improved treatment of
patient subgroups in which currently available therapies
may be of only limited benefit, such as patients with joint
involvement or those at risk of end-organ toxicity with
methotrexate, or for whom monotherapy has not yielded a
desired benefit. Although combination therapy may
improve treatment outcomes compared with individual
monotherapy, the efficacy benefit from combination treat-
ment can still remain below the desired target. The
potential importance of higher treatment goals being
achieved by monotherapy is highlighted by the emergence
of new biologic therapies, such as IL-17A inhibitors. These
agents selectively target key processes in the pathogenesis
of psoriasis and thus may offer better efficacy than current
biologic and systemic therapies. Therefore, these agents
may allow more patients and prescribers to meet their
psoriasis management goals without the need to augment
treatment regimens with additional agents.
Table 4 Biologic therapies currently under development for the treatment of psoriasis [100–103]
Agent Description Mechanism of action Current status
Secukinumab Fully human monoclonal antibody directed
against IL-17A
Blockade of IL-17A action In phase III clinical trials
Brodalumab Monoclonal antibody directed against
IL-17 receptor
Blockade of IL-17A action In phase III clinical trials
Ixekizumab Monoclonal antibody directed against IL-17 Blockade of IL-17A action In phase III clinical trials
Guselkumab (CNTO1959) Fully human HuCAL-based antibody directed
against the p19 subunit of IL-23
Blockade of IL-23 action In phase II clinical trials
MK-3222/SCH-900222 Humanized monoclonal antibody directed against
the p19 subunit of IL-23
Blockade of IL-23 action In phase III clinical trials
Tregalizumab (BT-061) Monoclonal antibody directed against CD4 cells Activation of regulatory T cells In phase II clinical trials
HuCAL human combinatorial antibody library, IL interleukin
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